{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:55:50Z","timestamp":1791158150457,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>T\u2010type Ca<jats:sup>2+<\/jats:sup> channels represent a specific channel family overexpressed in different types of tumours. Their involvement in controlling the proliferation, angiogenesis and invasion of tumour cells, has been partially clarified. The article by <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b1001\">Zhang <jats:italic>et\u2003al<\/jats:italic>.<\/jats:ext-link> in this issue of <jats:italic>BJP<\/jats:italic> provides the first evidence of anti\u2010tumoural effects of endostatin (ES) in U87 glioma cells. He demonstrated that ES or mibefradil (a L\/T\u2010type calcium channel blocker), reduces the proliferation and migration of U87 glioma cells in a T\u2010type Ca<jats:sup>2+<\/jats:sup> channel\u2010dependent manner. However, the difference in the blocking effect of mibefradil on T\u2010type calcium channel expression as compared with its ability to inhibit proliferation and migration, supports the idea of a broader T\/L\u2010type\u2010independent effect of the mibefradil blocker. Overall, these findings provide new insights for the future development of a novel class of anti\u2010T\u2010type calcium channel blockers in the therapy of glioblastoma.<\/jats:p><jats:p><jats:bold>LINKED ARTICLE<\/jats:bold> This article is a commentary on Zhang <jats:italic>et\u2003al<\/jats:italic>., pp. 1247\u20131260 of this issue. To view this paper visit <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/j.1476-5381.2012.01852.x\">http:\/\/dx.doi.org\/10.1111\/j.1476\u20105381.2012.01852.x<\/jats:ext-link><\/jats:p>","DOI":"10.1111\/j.1476-5381.2012.01908.x","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T17:28:11Z","timestamp":1329845291000},"page":"1244-1246","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Functional role of T\u2010type calcium channels in tumour growth and progression: prospective in cancer therapy"],"prefix":"10.1111","volume":"166","author":[{"given":"Giorgio","family":"Santoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Nabissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2006.04.014"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3501"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2006.04.017"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2005.09.005"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2007.03.006"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2006.04.029"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2004.07.002"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2006.117440"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.032"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05759.x"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01852.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2012.01908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2012.01908.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:29:58Z","timestamp":1697408998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2012.01908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1476-5381.2012.01908.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01908.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]},"assertion":[{"value":"2012-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}